Organization
University of Sheffield
7 abstracts
Abstract
A modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics (PKs) and anti-tumour activity of a first-in-class (FIC) specific dUTPase inhibitor CV6-168 combined with anti-cancer treatments in patients (pts) with advanced malignancies.Org: Newcastle University and Northern Centre for Cancer Care, University of Sheffield, CV6 Therapeutics (NI) Ltd, Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust,
Abstract
SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.Org: University of Sheffield, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy Département d'Organisation du Parcours Patient, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.Org: Mayo Clinic, Dana-Farber Cancer Institute, Mayo Clinic Department of Digital Health, Dow Medical College, Karachi, Pakistan, Mayo Clinic Department of Pediatric and Adolescent Medicine,
Abstract
SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—A UK phase III randomised multi-centre trial.Org: Queen's University Belfast, University of Cambridge, University of Oxford, Western General Hospital, University of Birmingham,
Abstract
A NATIONAL AUDIT OF PATIENTS WITH RHEUMATOID ARTHRITIS OF BLACK AND MINORITY ETHNIC ORIGIN Org: University Hospitals Of Leicester NHS Trust, Nottingham University Hospitals NHS Trust, University of Sheffield, Barking, Havering and Redbridge University Hospitals NHS Trust,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PALACE 4 PHASE 3, RANDOMIZED, CONTROLLED TRIAL Org: Celgene Corporation, University Hospital Southampton NHS Foundation Trust, Rheumatology and Immunotherapy Center, Franklin, United States of America, University of Sheffield, Altoona Center for Clinical Research, Duncansville, United States of America,
Abstract
ASSOCIATION BETWEEN ETHNICITY AND INITIAL RESPONSE TO TNF INHIBITORS IN PEOPLE WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS (BSRBR-RA)Org: The University of Manchester and The Christie NHS Foundation Trust, Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, Oxford University Hospitals NHS FT,